Does hydroxychloroquine improve patient reported outcomes in patients with lupus?
Fiche publication
Date publication
juillet 2021
Journal
Lupus
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DEVILLIERS Hervé
Tous les auteurs :
Jolly M, Sehgal V, Arora S, Azizoddin D, Pinto B, Sharma A, Devilliers H, Inoue M, Toloza S, Bertoli A, Blazevic I, Vilá LM, Moldovan I, Torralba KD, Mazzoni D, Cicognani E, Hasni S, Goker B, Haznedaroglu S, Bourre-Tessier J, Navarra SV, Clarke A, Weisman M, Wallace D, Mok CC
Lien Pubmed
Résumé
Hydroxychloroquine (HCQ) use is associated with less disease activity, flares, damage and improved survival in Systemic Lupus Erythematosus (SLE). However, its effect on patient reported health outcomes (PROs) such as quality of life (QOL) is not known.
Mots clés
Quality of life, systemic lupus erythematosus, disease activity, damage, hydroxychloroquine
Référence
Lupus. 2021 Jul 26;:9612033211033983